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Differential genome-wide array–based methylation profiles in prognostic subsets
of chronic lymphocytic leukemia
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Richard Rosenquist1
1Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden; 2School of Biological Sciences, Dublin Institute of Technology (DIT), Dublin,
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Global hypomethylation and regional hy-
permethylation are well-known epige-
netic features of cancer; however, in
chronic lymphocytic leukemia (CLL), stud-
ies on genome-wide epigenetic modifica-
tions are limited. Here, we analyzed the
global methylation profiles in CLL, by
applying high-resolution methylation mi-
croarrays (27 578 CpG sites) to 23 CLL
samples, belonging to the immunoglobu-
lin heavy-chain variable (IGHV) mutated
(favorable) and IGHV unmutated/IGHV3-21
(poor-prognostic) subsets. Overall, re-
sults demonstrated significant differ-
ences in methylation patterns between
these subgroups. Specifically, in IGHV
unmutated CLL, we identified methyl-
ation of 7 known or candidate tumor
suppressor genes (eg, VHL, ABI3, and
IGSF4) as well as 8 unmethylated genes
involved in cell proliferation and tumor
progression (eg, ADORA3 and PRF1 en-
hancing the nuclear factor-B and
mitogen-activated protein kinase path-
ways, respectively). In contrast, these lat-
ter genes were silenced by methylation in
IGHV mutated patients. The array data
were validated for selected genes using
methylation-specific polymerase chain re-
action, quantitative reverse transcriptase–
polymerase chain reaction, and bisulfite
sequencing. Finally, the significance of
DNA methylation in regulating gene pro-
moters was shown by reinducing 4 meth-
ylated tumor suppressor genes (eg, VHL
and ABI3) in IGHV unmutated samples
using the methyl-inhibitor 5-aza-2-deoxy-
cytidine. Taken together, our data for the
first time reveal differences in global meth-
ylation profiles between prognostic sub-
sets of CLL, which may unfold epigenetic
silencing mechanisms involved in CLL
pathogenesis. (Blood. 2010;115:296-305)
Introduction
Chronic lymphocytic leukemia (CLL) is characterized by clonal
proliferation and accumulation of long-lived neoplastic B cells,
which arise due to altered control of apoptosis as well as
proliferation. No common disease-causing mutation has yet
been identified in CLL, although certain recurrent genomic
aberrations (ie, 11q, 12, 13q, 17p) provide important
prognostic information.1 Besides these aberrations, the mutation
status of the immunoglobulin heavy-chain variable (IGHV)
genes segregates patients into 2 main prognostic subgroups,
where patients with unmutated IGHV genes show inferior
outcome compared with those with mutated IGHV genes.2,3 In
addition, CLL patients using the IGHV3-21 gene display poor
outcome independent of mutation status.4
Aberrant DNA methylation has been shown to play a strong role
in tumorigenesis, where genome-wide hypomethylation and re-
gional hypermethylation of tumor suppressor gene promoters are
characteristic hallmarks of many cancers.5 In CLL, the epigenetic
mechanism of gene regulation has thus far received limited
attention. That notwithstanding, a strong correlation between
promoter methylation and transcriptional silencing was shown for
certain individual gene promoters in CLL, for example, DAPK1,
TWIST2, ZAP70, and HoxA4.6-9 The methylation status of several
of these genes has also been reported to correlate with IGHV
mutational status. To date, only one study has been performed
using genome-wide methylation analysis in CLL using the “Restric-
tion Landmark Genomic Scanning” technique. They observed that
2% to 8% of CpG islands were aberrantly methylated compared
with normal controls and that methylation events showed a
nonrandom distribution.10 However, this technique spans only
3000 CpG islands and does not give a full coverage of the genome.
The main aim of this present investigation was to study and
compare the genome-wide methylation profiles of different CLL
prognostic subgroups to identify differentially methylated genes
that can play a role in CLL pathogenesis. Recent studies have
revealed that DNA hypermethylation in cancer is not always
restricted to discrete CpG islands or single genes but can affect
multiple adjacent CpG-rich regions resulting in gene silencing
across large genomic distances.11 Unlike promoter CpG island
methylation arrays that cover sites near the promoter region, we
here applied an Illumina Infinium HumanMethylation27 array
(27 578 methylated sites, covering 14 495 genes) to 23 CLL patient
samples belonging to the IGHV mutated, IGHV unmutated, and
IGHV3-21 CLL subgroups. We identified distinct methylation
profiles between different subgroups and the array data were
validated for selected genes using methylation-specific primer
(MSP) polymerase chain reaction (MSP-PCR), real-time quantita-
tive PCR (RQ-PCR) and bisulfite sequencing. Finally, methylated
genes were also reexpressed in CLL patient samples using methyl
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inhibitors to ascertain the role of DNA methylation in regulating
gene expression.
Methods
Patient samples and clinical data
In this study, 23 tumor samples from patients with CLL (6 IGHV mutated,
7 IGHV unmutated, and 10 IGHV3-21) were collected from the Biobank at
the Department of Pathology, Uppsala University Hospital (Uppsala,
Sweden). All samples were diagnosed according to recently revised
criteria,12 showing typical CLL immunophenotype and 70% or more tumor
cells. Clinical and molecular characteristics including IGHV mutation
status and genomic aberrations are summarized in Table 1. Two normal
healthy control samples (1 sample with peripheral blood mononuclear cells
[PBMC]) and 1 sample with CD19 sorted B cells) and 1 negative control
(whole-genome amplified DNA) were included for analysis. In addition,
2 CLL Epstein-Barr virus (EBV)–transformed cell lines (I83 derived from a
mutated CLL patient and HG3 derived from an unmutated CLL patient)
were included for analysis. Finally, 10 additional CLL samples (5 IGHV
mutated and 5 IGHV unmutated) were included in the validation experi-
ments using MSP-PCR and another 50 CLL samples (27 IGHV mutated and
23 IGHV unmutated) were included in RQ-PCR analysis. None of these
60 latter samples were included in methylation array analysis. Informed
consent was obtained according to the Declaration of Helsinki and the study
was approved by the ethical review committee of Uppsala University.
Methylation array analysis
We applied the genome-wide Illumina Infinium HumanMethylation27
BeadChip array (Illumina) which allows interrogation of 27 578 CpG
dinucleotides, covering 14 495 genes. First, bisulfite conversion of genomic
DNA was performed using the EZ DNA Methylation Kit (Zymo Research)
according to the manufacturer’s protocol. Briefly, 1 g of DNA was sodium
bisulfite treated, denatured at 95°C for 30 seconds, and bisulfite converted
at 50°C for 12 hours. After conversion, samples were desulphonated and
eluted using column preparation. Approximately 100 to 125 ng of bisulfite-
converted DNA was processed according to the Illumina Infinium Methyl-
ation Assay protocol. This assay is based on the conversion of unmethylated
C-nucleotides into U(T) nucleotides by the bisulfite treatment. The DNA
was whole-genome amplified, enzymatically fragmented, precipitated,
resuspended, and hybridized overnight at 48°C to locus-specific oligonucle-
otide primers on the BeadArray. After hybridization, the C or T nucleotides
were detected by single-base primer extension. The fluorescence signals
corresponding to the C or T nucleotides were measured from the BeadAr-
rays using an Illumina BeadStation GX scanner. The fluorescence data were
then analyzed using the BeadStudio software (Illumina), which assigns a
quantitative measure of the methylation levels ( value or methylation
index [MI] value) for each CpG site, that corresponds to the ratio between
the fluorescence signal from the methylated allele (C) and the sum of the
fluorescent signals of the methylated (C) and unmethylated (T) alleles. The
methylation status for each detected CpG site ranged between 0.1 (com-
pletely unmethylated) to 1 (completely methylated). MI cutoffs of 0.7 or
Table 1. Clinical and molecular data for the CLL patients included
CLL sample Percent identity* Age at diagnosis, y Sex Survival, mo† Binet stage Treated before sampling‡ Genomic aberrations§
IGHV mutated
M1 94.6 63 M 195¶ A No del(13q)3
M2 91.5 74 M 55 A No del(13q)1
M3 93.2 72 M 129¶ A ND None3
M4 94.1 70 M 134¶ A No del(13q)3
M5 91.3 65 M 104¶ A No del(13q)1
M6 91.1 64 F 94¶ A No None3
IGHV unmutated
UM1 100.0 49 M 99 A Yes del(11q)3
UM2 100.0 44 M 84 B ND del(11q)3
UM3 100.0 79 M 10 B No ND
UM4 100.0 82 F 50 B No ND
UM5 100.0 57 M 49 B No del(13q)1
UM6 100.0 69 M 24 C No None3
UM7 100.0 51 M 112¶ A No None1
IGHV3-21
3-21-1 100.0 45 F 58 ND ND 122
3-21-2 100.0 63 M 58 C No del(13q), del(11q)1
3-21-3 96.50# 61 M 52 C No del(13q),del(11q)1
3-21-4 96.9# 62 F 67 ND No del (13q)2
3-21-5 100.0 65 F 52 ND Yes del(17p),121
3-21-6 98.7# 67 M ND ND ND del(13q),del(11q)1
3-21-7 96.49# 63 M ND ND ND del(13q)3
3-21-8 95.5# 60 M 72 B No None1
3-21-9 96.8# 62 M 111 ND ND del(13q)2
3-21-10 97.4# 76 M 82 A No del(13q), del(11q)2
ND indicates not defined.
*IGHV gene analysis was performed using PCR amplification and nucleotide sequencing as previously described.13 Cases with 98% identity to germline were classified
as unmutated, whereas cases with 98% identity were considered mutated. IGHV3-21 cases were classified as stereotyped (#) or nonstereotyped according to Murray et al.13
† indicates months from diagnosis to last observation or death; and ¶ indicates that the patient is alive.
‡ denotes treatment status before sampling; yes indicates that the patient was treated before sampling; and no indicates that the patient remained untreated.
§Known recurrent aberrations, that is, del(13q), del(11q), del(17p) and trisomy 12, were determined using fluorescence in situ hybridization (FISH) analysis (1), SNP-array
analysis (2) or quantitative PCR analysis (3). FISH analysis was performed using commercially available probes as decribed previously,14 whereas single nucleotide
polymorphism (SNP) array analysis was performed using high-resolution Affymetrix 250K SNP arrays from which data on known recurrent genomic aberrations were
extracted.14 Quantitative PCR was performed by applying specifically designed primers for each locus (primers available on request) using the SYBR Green master mix
according to the manufacturer’s protocol (Fermentas). Copy-number changes were normalized against a copy-number neutral internal control region and ratios relative to the
DNA copy number from a pooled control (Promega) were tallied for each locus.
A second mutated, in-frame IGHV gene rearrangement (92% identity) was also detected in this case.
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more and 0.4 or less (average of all MI values in each group) were
considered methylated and unmethylated, respectively.
Further bioinformatic analysis of the methylation data were carried out
in the freely available statistical computing language R (http://www.
r-project.org). To search for the differentially methylated genes between the
different prognostic subgroups (ie, IGHV mutated/unmutated and IGHV3-21
CLL patients), the data were arcsin transformed and an empirical Bayes
moderated t test was then applied using the “limma” package. The P values
were adjusted using the method of Benjamini and Hochberg15 and a level of
P less than .05 was used as a cutoff. To identify differentially methylated
genes of largest difference between subgroups, an additional filter incorpo-
rating the average geometric difference was applied to ensure only genes
with large absolute differences remained. Consequently, an average differ-
ence in MI of 0.45 between the IGHV mutated and IGHV unmutated
subgroups, 0.35 between the IGHV3-21 and IGHV mutated subgroups, and
0.35 between IGHV3-21 and IGHV unmutated subgroups was applied.
MSP-PCR analysis
To verify the findings from the methylation arrays, we selected 4 genes for
MSP-PCR. MSP were designed according to MSP selection criteria as
outlined by Li and Dahiya.16 Specifically, sequences covering approxi-
mately 250 bp flanking the identified CpG sites on either side were used for
primer design in the Methprimer software (Bisearch). The unmethylated-
specific primers (USP) were designed around 50 bp upstream and down-
stream of the MSP, as to cover the same CpG sites as those contained by the
MSP region. Both MSP and USP are listed in supplemental Table
1 (available on the Blood website; see the Supplemental Materials link at
the top of the online article). The PCRs contained 1.5mM MgCl2, 200M
dNTP mix (Invitrogen), 0.2M primers (Sigma-Aldrich), 1 PCR Ampli-
Taq gold buffer, 1.25 U of AmpliTaq Gold (Applied Biosystems), 5%
dimethyl sulfoxide (DMSO; Merck) and 50 ng of bisulfite-treated DNA.
The PCR was performed as follows: denaturation at 95°C for 10 minutes;
35 cycles of 94°C for 45 seconds, 58°C for 45 seconds, 72°C for 45 seconds
and a final extension step of 72°C for 5 minutes. The PCR products were
visualized on 2% agarose gels containing ethidium bromide.
RQ-PCR analysis
To further analyze whether methylation status influences the gene expres-
sion of specific genes, we selected 4 genes for RQ-PCR. Total RNA was
extracted using the RNA Extraction Kit (QIAGEN) according to the
manufacturer’s protocol. The reverse transcription (RT) reaction was
performed using the MMLV-RT Kit (Invitrogen) and random hexamers
(Fermentas) according to the manufacturer’s protocol. RT-PCR primers
were designed using the Primer3 software (Broad Institute). All primer
sequences are listed in supplemental Table 1. Quantitative RT-PCR analysis
was performed using 2 SYBR Green master mix according to manufactur-
er’s protocol (Fermentas). Expression was analyzed using the Stratagene
Mx 3005p (Stratagene) detection system and calculated with the Max Pro
QPCR software (Stratagene) using beta-actin as a reference gene and the
 cycle threshold (Ct) method. The statistical significance of differences
in expression was calculated by a t test and represented in box plot graphs
using Statistica 8.0 software (Stat Soft).
Bisulfite sequencing
To confirm the methylation status of individual genes, we selected 2 genes
for bisulfite sequencing. Bisulfite-sequencing primers (BSP) were designed
according to BSP selection criteria as outlined by Li and Dahiya16
(supplemental Table 1). PCR was performed using 1.5mM MgCl2, 200M
dNTP mix, 0.2M primers (Sigma-Aldrich), 1 PCR Taq buffer, 1 U of
Platinum Taq (Invitrogen), and approximately 50 ng of bisulfite-treated
DNA. Touchdown PCR cycling conditions included 5 cycles at 95°C for
30 seconds, 55°C for 45 seconds, and 72°C for 1 minute, followed by
5 cycles at 95°C for 30 seconds, 53°C for 45 seconds, and 72°C for
1 minute, and a further 30 cycles at 94°C for 30 seconds, 50°C for
45 seconds, and 72°C for 45 seconds, followed by a final extension step of
72°C for 5 minutes. The PCR product was cloned using the Invitrogen
TOPO TA Cloning Kit 2.1 TOPO vector (Invitrogen), and 10 to 12 clones
per sample were selected for verification of the correct-sized insert via PCR
using vector-specific M13 forward and reverse primers (provided by the
cloning kit). Verified PCR products were treated using 0.5 U of ExoI and
1.0 U of shrimp alkaline phosphatase (Fermentas) at 37°C for 45 minutes
and 80°C for 15 minutes and sequenced with vector-specific primers using
the BigDye Terminator Cycle Sequencing Reaction Kit (Perkin-Elmer). All
sequence reactions were analyzed using an automated DNA sequencer
(ABI 377; Applied Biosystems). Sequences were aligned and analyzed
using the bisulfite sequencing web-based tool BiQ Analyzer software
(Max-Planck Institut fur Informatik, Saarbrucken, Germany) and the degree
of methylation represented as a lollipop grid.
DAC and TSA treatment
Frozen primary CLL cell samples and the CLL cell line HG3 were cultured
in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS;
Sigma-Aldrich), 4mM glutamine, and 1 penicillin/streptomycin (Invitro-
gen) until confluent. Cells were then subdivided to contain approximately
1 million cells/mL per well 12 hours before treatment, to allow the cells to
adjust to conditions. Cells were subsequently cultured over 3 days in
supplemented RPMI media treated with one of the following treatments:
(1) medium containing 5-aza-2-deoxycytidine (DAC; 5M/L, Sigma-
Aldrich) for 72 hours whereby medium was changed every 24 hours;
(2) medium containing trichostatin A (TSA, 500nM/L; Sigma-Aldrich) for
the last 24 hours; and (3) medium containing DAC for 48 hours followed by
addition of TSA for 24 hours. Control cells were cultured in similar way
with no drugs added.
Results
Distribution of samples based on overall MI
This study investigated a total of 27 samples, encompassing
6 IGHV-mutated, 7 IGHV-unmutated, and 10 IGHV3-21 CLL
patient samples, as well as 2 healthy control samples (1 obtained
from peripheral blood mononuclear cell [PBMC] and 1 from sorted
B cells), 2 EBV-transformed CLL cell lines and 1 negative control
(whole genome–amplified DNA). Figure 1 graphically represents
the MI values obtained from all samples. As expected, the negative
control sample showed lowest MI and the healthy control samples
displayed the highest values. All CLL patient samples fell in the
range between these controls, whereas the 2 CLL cell lines
displayed lower MIs compared with the CLL samples. Hence,
healthy controls had a higher degree of genome-wide methylation,
whereas the CLL cell lines showed less methylation compared with
the CLL patient samples.
Methylation profiling of different prognostic subgroups of CLL
Genome-wide methylation profiles were compared between samples
from 3 different CLL subgroups, that is, IGHV mutated, IGHV
unmutated, and IGHV3-21 CLL. In addition, healthy controls were
included for comparison. Because the CLL cell lines showed
completely different methylation profiles compared with CLL
patient samples, these were not included in the comparisons. Using
highly stringent selection criteria (as detailed in “Methylation array
analysis”), a total of 64 genes were identified as significantly
differentially methylated between IGHV mutated and unmutated
CLL (Figure 2A). Similarly, 60 and 31 genes were identified in the
comparison between IGHV unmutated versus IGHV3-21 CLL and
IGHV mutated versus IGHV3-21 CLL, respectively (Figure 2B-C).
Based on the functionality of all these identified differentially
methylated genes, they could be grouped into various categories,
such as apoptotic-related genes (antiapoptotic or proapoptotic),
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known or candidate tumor suppressor genes, genes involved in
high proliferative activity, genes enhancing tumorigenesis, drug-
resistance genes, and genes associated with prognosis, as described
in Table 2. Importantly, we identified known/candidate tumor
suppressor genes that were preferentially methylated in the IGHV
unmutated (7 genes, eg, VHL, ABI3), IGHV3-21 (1 gene,
SLC22A18), and IGHV mutated (2 genes, PPP1R3A and WISP3)
subgroups. We also identified 10 unmethylated and hence poten-
tially expressed genes shown to be involved in activation of
proliferative pathways such as the nuclear factor 	B (NF	B)
pathway (eg, ADORA3 and CARD15), and the mitogen-activated
protein/extracellular signal–regulated kinase (MAPK/ERK) kinase
pathway (eg, PRF1 and FABP7) in the IGHV unmutated and
IGHV3-21 subgroups. Of the identified genes, most have previ-
ously not been associated with CLL; however, many were known
to be involved in the tumorigenesis of several other cancers
and leukemia.
Confirmation of array data using MSP-PCR and RQ-PCR
To confirm the array data, we selected 4 genes for MSP-PCR: that
is, PRF1 and ADORA3 (methylated in IGHV mutated CLL
Figure 1. MI for the 27 samples included in the
present study.
Figure 2. Supervised hierarchical clustering of methylated/unmethylated genes between CLL subgroups. Three different comparisons were made: (A) IGHV mutated
(samples M1 to M6) versus IGHV unmutated (samples UM1 to UM7), (B) IGHV unmutated versus IGHV3-21 (samples 3-21-1 to 3-21-10), and (C) IGHV mutated versus
IGHV3-21. Two normal healthy control samples and 1 negative control were included for comparison. A gradient color scale ranging between green (completely unmethylated)
and red (completely methylated) is included.
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Table 2. Functional characterization of selected differentially methylated genes
Functionality of genes/gene names
IGHV
mutated
IGHV
unmutated IGHV3-21 Implicated role in cancer
Accession
number Reference
IGHV mutated and IGHV unmutated CLL
Tumor-suppressor genes
ABI3* Unmethylated Methylated Lost in cancer cell lines, implicated in lung
metastasis
NM_016428.3 17
SCGB2A1* Unmethylated Methylated Methylated in lung cancer NM_002407.1 18
VHL Unmethylated Methylated Mutated in sporadic cell renal carcinoma
and von Hippel-Lindau syndrome
NT_022517.17 19
PPP1R3A* Methylated Unmethylated Deregulated in colorectal cancer NM_002711.2 20
WISP3 Methylated Unmethylated Loss of expression in inflammatory breast
cancer
NM_003880.2 21
Genes enhancing proliferation
ADORA3 Methylated Unmethylated Activation of the NF	B pathway NM_020683.5 22
AIRE Methylated Unmethylated Regulated by the PKC pathway NM_000383.1 23
CARD15 Methylated Unmethylated Activation of the NF	B pathway NM_022162.1 24
FABP7 Methylated Unmethylated Regulated by the MAPK/ERK pathway NM_001446.3 25
LOC340061 Methylated Unmethylated Activation of the NF	B pathway NM_198282.1 26
PRF1 Methylated Unmethylated Enhancing the MAPK pathway NM_005041.3 27
UNC5CL Methylated Unmethylated Activation of the NF	B pathway NM_173561.1 28
Genes facilitating tumorigenesis
ANGPT2 Methylated Unmethylated Preferentially expressed in unmutated
CLL
NM_001147.1 29
IFNB1 Methylated Unmethylated Shown to enhance B-cell proliferation NM_002176.2 30
URP2 Methylated Unmethylated Implicated in facilitating CLL
tumorigenesis
NM_031471.4 31
Antiapoptotic genes
BCL2 Methylated Unmethylated Known antiapoptotic gene, up-regulated
in many cancers
NT_025028.13 32
PLD1 Unmethylated Methylated Stimulates cell-cycle progression by
repressing p53 regulation of p21
NM_002662.2 33
Proapoptotic genes
BCL10 Unmethylated Methylated Proapoptotic genes, involved in p53
mediated cell death
NM_003921.2 34
IL19 Methylated Unmethylated Regulating apoptosis by activation of the
STAT3 pathway
NM_013371.2 35
Genes involved in prognosis
NGFR Unmethylated Methylated Highly expressed in favorable prognostic
ALL patients
NM_002507.1 36
IGHV unmutated and IGHV3-21 CLL
Tumor-suppressor genes
ABI3* Methylated Unmethylated Lost in cancer cell lines, implicated in lung
metastasis
NM_016428.3 17
GPX3 Methylated Unmethylated Deleted or methylated in prostate cancer NM_002084.2 37
IGSF4* Methylated Unmethylated Down-regulated by methylation in
neuroblastoma
NM_014333.2 38
SERPIND5* Methylated Unmethylated Tumor-suppressive properties in breast
cancer
NM_002639.2 39
SLC22A18 Unmethylated Methylated Deregulated in several cancer forms NM_183233.1 40
Genes repressing proliferation
LDOC1 Unmethylated Methylated Implicated in repressing the NF	B
pathway
NM_012317.2 41
ZNF540 Methylated Unmethylated Involved in down-regulating the MAPK
pathway
NM_152606.2 42
Genes facilitating tumorigenesis
IL17RC Unmethylated Methylated Shown to facilitate tumorigenesis in
prostate cancer
NM_032732.2 43
ANGPT2 Unmethylated Methylated Expressed in IGHV unmutated CLL NM_001147.1 29
FHL2 Methylated Unmethylated NM_201556.1
S100A14 Unmethylated Methylated NM_020672.1
Antiapoptotic genes
BCL2 Unmethylated Methylated Known antiapoptotic gene, up-regulated
in many cancers
NT_025028.13 32
PLD1 Methylated Unmethylated Stimulates cell-cycle progression by
repressing p53 regulation of p21
NM_002662.2 33
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samples) and BCL10 and IGSF4 (methylated in IGHV unmutated
CLL samples). PRF1 and ADORA3 are mainly involved in cell
proliferation by constitutive activation of the mitogen-activated
protein kinase (MAPK) and NF	B pathways, respectively,22,27
whereas BCL10 is an antiapoptotic gene34 and IGSF4 is a candidate
tumor suppressor gene.38 Figure 3A illustrates the results for
3 IGHV mutated and 4 unmutated CLL samples, verifying that
PRF1 and ADORA3 were mostly methylated in mutated samples,
whereas mostly BCL10 and IGSF4 were methylated in unmutated
samples. In addition, we selected 10 additional IGHV mutated and
unmutated CLL samples (not included in the array study), and
analyzed the methylation status for ADORA3 and BCL10, which
further confirmed the divergent methylation status between the
mutated/unmutated CLL subgroups (Figure 3B).
After conformation of the methylation status of the selected
genes, we correlated these data with mRNA expression levels of
the respective genes as well as 3 additional genes (ie, VHL, ABI3,
and NGFR) using RQ-PCR. Figure 4 demonstrates RQ-PCR results
for 4 of the genes (VHL, ABI3, ADORA3, and BCL-10) in a CLL
cohort of 50 samples, confirming that the mRNA expression levels
correlated strongly with the methylation status. Of the 4 genes
analyzed, 3 genes (VHL, ABI3, and BCL-10) showed a significant
difference between the IGHV mutated and unmutated subgroups.
Furthermore, RT-PCR results for the PRF1 and NGFR genes
(supplemental Figure 1) were analyzed on the same 4 IGHV
mutated and unmutated samples included in the MSP-PCR analy-
ses, further verifying the MSP-PCR data.
Bisulfite sequencing of methylated tumor suppressor genes
Two candidate tumor suppressor genes (VHL and ABI3) that
displayed significant differences in gene expression levels between
IGHV mutated and unmutated CLL samples were selected for
bisulfite sequencing and subcloning to confirm the degree of
methylation using 2 IGHV mutated and 2 IGHV unmutated
samples. The bisulfite sequencing region covered the CpG sites
Table 2. Functional characterization of selected differentially methylated genes (continued)
Functionality of genes/gene names
IGHV
mutated
IGHV
unmutated IGHV3-21 Implicated role in cancer
Accession
number Reference
IGHV mutated and IGHV3-21 CLL
Genes enhancing proliferation
LOC340061 Methylated Unmethylated Activation of the NF	B pathway NM_198282.1 26
PRF1 Methylated Unmethylated Enhancing the MAPK pathway NM_005041.3 27
RASGRP3 Methylated Unmethylated Regulated B-cell proliferation by
facilitating B-cell receptor–RAS
signaling
NM_170672.1 44
Genes facilitating tumorigenesis
LMO2 Methylated Unmethylated Known proto-oncogene, expressed in
human B-cell lymphomas
NM_005574.2 45
URP2 Methylated Unmethylated Implicated in facilitating CLL
tumorgenesis
NM_031471.4 31
NCRMS Methylated Unmethylated XR_000219.2
Proapoptotic genes
TP53I3 Methylated Unmethylated Shown to induce p53-mediated cell death NM_004881.2 46
BCL10 Unmethylated Methylated Proapoptotic genes, involved in p53-
mediated cell death
NM_003921.2 34
Genes involved in prognosis
DNTT Methylated Unmethylated Associated with poor prognosis in acute
myeloid leukemia
NM_004088.3 47
*These genes represent candidate tumor-suppressor genes.
Figure 3. Validation experiments using MSP-PCR.
MSP-PCR was performed for the PRF1, ADORA3,
BCL10, and IGSF4 genes, using bisulfite-treated DNA
from IGHV mutated samples (M1-3 to M8-12) and IGHV
unmutated samples (UM1-4 and UM8-12). (A) Data for
samples analyzed in the methylation array; (B) results
from additional CLL samples are included. Analysis of
each gene in panels A and B was performed during the
same experiment and on the same gel; vertical line(s)
have been inserted to indicate a repositioned gel lane. N
indicates normal PBMC sample; M, methylation-specific
primers; and U, unmethylation-specific primers.
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which were included in the array and showed a significant
difference in the MI values between IGHV mutated and IGHV
unmutated samples. Both genes exhibited a high degree of
hypermethylation in the IGHV unmutated samples compared with
the IGHV mutated samples (Figure 5).
Reexpression of methylated genes using a methyl inhibitor
To investigate the role of DNA methylation in transcriptional
regulation of gene promoters, we examined the effects of DNA
methyl transferase inhibitor DAC and/or histone deacetylase
inhibitor TSA treatment on gene expression in 3 IGHV unmutated
and 3 IGHV mutated CLL samples. Four genes found to be mainly
hypermethylated in unmutated samples (IGSF4, VHL, ABI3, and
NGFR) were selected for reexpression analysis. An increase in the
activation of the IGSF4, ABI3, and VHL genes was observed in
response to DAC or TSA treatment, especially when applied in
combination, in several of the IGHV unmutated CLL samples
compared with the corresponding untreated samples (Figure 6).
Reactivation of the NGFR gene is shown in supplemental Figure 2.
Similar data were obtained for all the above-mentioned genes using
the CLL EBV transformed cell line HG3 (data not shown).
Discussion
In hematologic malignancies, genes involved in important cellular
pathways have been described to be affected by CpG island
methylation in association with transcriptional silencing.48 The role
of aberrant DNA methylation and individual DNA promoter
methylation has been investigated in CLL (eg, ZAP-70, TWIST
2),6,7 although there have been few comprehensive studies dedi-
cated to uncover the methylation status on a global level. Using a
genome-wide methylation array, we here for the first time identified
distinct methylation profiles in prognostic subsets of CLL.
In tumor cells, a disrupted methylation pattern is often observed
featuring global hypomethylation and region-specific hypermethyl-
ation of certain gene promoters, compared with their normal
Figure 4. Validation experiments using quantitative RT-PCR.
Relative expression data presented as box plots for the following
genes: VHL, ABI3, ADORA3, and BCL10. Twenty-seven IGHV
unmutated and 23 IGHV mutated CLL cases were investigated
that had been not included in the methylation array analysis.
Values of P are indicated above each box plot. Boxes indicate the
interquartile range (25%-75%) with the smaller inner square
indicating the median. The whiskers show the minimum and
maximum values, except for outliers (E).
Figure 5. Bisulfite sequencing of 2 tumor suppressor genes. (A) VHL and
(B) ABI3. Results from 2 IGHV mutated and 2 IGHV unmutated CLL samples are
shown. Black lollipops indicate methylated CpG sites; and white lollipops, unmethyl-
ated CpG sites.  indicates a polymorphic site.
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cellular counterparts. In the present study, the overall degree of
methylation, indicated as MI values, of all CLL primary samples
demonstrated lower methylation levels compared with normal
healthy controls (Figure 1), which is in line with previous
findings.49 We also noticed that the EBV-transformed CLL cell
lines displayed very different methylation patterns compared with
CLL primary samples with lower MI values. This is perhaps not
unexpected considering their higher proliferative capacity.
To identify differentially methylated genes between CLL subgroups,
we applied a stringent bioinformatic approach which revealed signifi-
cantly different methylation profiles between IGHV unmutated and
mutated CLL as well as between IGHV mutated/unmutated and
IGHV3-21 CLL (Figure 2). Many of the identified genes were found to
be involved in important cellular pathways, where dysregulation of
these genes could significantly contribute to leukemogenesis. For
instance, we identified known or candidate tumor suppressor genes that
were preferentially methylated in the poor-prognostic IGHV unmutated
(7 genes) and IGHV3-21 (1 gene) subgroups (Table 2). Although many
of these genes have been implicated in several other cancers (Table 2),
their role in CLL has not been investigated. Some of the known or
candidate tumor suppressor genes that were specifically methylated in
IGHV unmutated CLL were: ABI3, implicated in lung metastasis,17
VHL, mutated in sporadic renal cell carcinoma as well as in the
hereditary syndrome von Hippel-Lindau19 and IGSF4, methylated in
neuroblastoma.38 Furthermore, we performed validation experiments to
verify the methylation data from the arrays. For instance, the high degree
of methylation and the corresponding decreased gene expression of
2 genes, VHL and ABI3, were confirmed by both bisulfite sequencing
and RQ-PCR in IGHV unmutated CLL(Figure 4 and 5). Taken together,
several tumor suppressor genes were found methylated particularly in
poor-prognostic, unmutated CLL, while they remained unmethylated
and hence expressed in IGHV mutated CLL.
Previous studies implicate that certain cellular pathways, such
as NF	B, phosphatidylinositol 3-kinase (PI3K)/Akt and MAPK/
ERK, are dysregulated in CLL B cells leading to activation of
antiapoptotic pathways. Our data strengthens this idea and further
indicates that certain genes involved in such proliferative pathways
may be controlled by DNA methylation in CLL. In particular, we
identified expression of genes that enhance constant cell prolifera-
tion and invasion in the IGHV unmutated CLL subgroup (Table 2).
Some of the genes included were ADORA3 and PRF1 genes, that
activate the NF	B and MAPK pathways, respectively, and which
were expressed in the poor-prognostic CLL subsets compared with
IGHV mutated CLL.26,27 In addition, genes involved in repressing
the NF	B pathway (LCOD1 gene)29 and MAPK (ZNF540 gene)36
pathways were generally methylated in both IGHV unmutated and
IGHV3-21 samples in contrast to IGHV mutated CLL. The
methylation status and gene expression were confirmed for 2 such
genes—for example, ADORA3 and PRF1—using both MSP-PCR
and RQ-PCR in IGHV unmutated versus mutated CLL (Figure
3 and 4). Moreover, genes previously reported to be involved in
facilitating tumorigenesis within other cancer types were noted to
be preferentially unmethylated in the IGHV unmutated (7 genes)
and IGHV3-21 (4 genes) CLL subgroups in comparison to IGHV
mutated CLL (Table 2). For example, IFNB1, shown to enhance
B-cell proliferation,30 and IL17RC, involved in facilitating tumori-
genesis in prostate cancer,43 were unmethylated in IGHV unmu-
tated samples. Thus, the data indicates that poor-prognostic CLL
subsets favor expression of genes aiding tumor proliferation.
Both IGHV unmutated CLL and IGHV mutated CLL also
showed deregulation of anti- and proapoptotic genes. For example,
BCL2 and PLD1, which are known antiapoptotic gene,32,33 re-
mained unmethylated in IGHV unmutated and IGHV mutated CLL
samples, respectively. On the other hand, proapoptotic genes such
as BCL1034 and TP5313, shown to induce p53-mediated cell
death,46 were methylated in IGHV unmutated and IGHV mutated
CLL samples, respectively. As shown in Figure 3, we could confirm
both the differential methylation status and expression level of
BCL10 in mutated and unmutated CLL.
Interestingly, we also identified certain genes that have been
related to prognosis, for instance, the ANGPT2 gene which has
been shown to be expressed preferentially in IGHV unmutated
CLL samples.29 Our array data indeed demonstrated that this gene
was methylated in mutated CLL while being unmethylated in
unmutated CLL. In addition, expression of the NGFR gene, which
has been associated with favorable prognosis in ALL,36 was
unmethylated in IGHV mutated CLL and showed increased
expression on the RNA level within this subset (supplemental
Figure 1). However, further analysis of the ANGPT2 and NGFR
genes in a larger CLL cohort is needed to assess their prognos-
tic impact.
Apart from the “traditional” genes, the HumanMethylation27
BeadChip array also contains 110 miRNA promoters. However,
none of these miRNAs met the criteria set to define a significant
difference in methylation between the studied subsets. Evidently,
this does not exclude that methylation changes may exist between
CLL subsets considering that only a fraction of miRNA promoters
were covered by the array.
Unlike genetic changes, epigenetic changes are reversible using
demethylating agents such as DAC. Consequently, the role of these
agents as treatment options is currently under investigation in
Figure 6. RT-PCR analysis showing the reexpression of methylated tumor
suppressor genes in unmutated CLL. Three different candidate tumor suppressor
genes—(A) IGSF4, (B) ABI3, and (C) VHL—were investigated in 3 IGHV unmutated
CLL samples (UM1 to UM3, shown in different colors) with and without treatment
using the methyl inhibitor DAC, the HDAC inhibitor TSA, or in combination. Con
indicates control.
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hematologic malignancies including CLL.50,51 In this study, we
demonstrated that inhibition of DNA methylation using methyl-
and histone deacetyl (HDAC) inhibitors could induce expression of
methylated tumor suppressor genes (eg, IGSF4, ABI3, and VHL) in
unmutated CLL primary samples. We generally did not observe
high induction of gene expression with methyl inhibitor treatment,
probably because CLL primary cells do not proliferate at a high rate
under in vitro conditions, although the effect of the drugs was
pronounced when applied in combination. These data indeed
strengthen the role of DNA methylation in regulating promoter
expression and open up the possibility of targeted therapy, although
this has to be studied further.
Gene expression microarray studies have previously revealed
different gene expression profiles between IGHV mutated and
IGHV unmutated/IGHV3-21 CLL patients.52-54 However, the ma-
jority of the identified genes in the present study could not be found
in these gene expression studies.52-54 There could be several
possible explanations for this: for example, incomplete overlap
with genes included on the expression arrays and different criteria
applied for identifying genes differing between subsets. Gene
expression can also be silenced by other mechanisms than
methylation—for instance, mutations or deletions—which will not
be identified on methylation arrays. In addition, we cannot exclude
the possibility that differentially methylated genes may not always
correlate with a significant difference in gene expression. Because
this is one of the first studies using the whole-genome Illumina
array, we decided to apply stringent criteria to reduce false-positive
genes. On the other hand, we may indeed have lost some important
genes, which would have come up using less stringent criteria. That
notwithstanding, we believe that our confirmation experiments
using different techniques such as MSP-PCR, RQ-PCR, and
bisulfite sequencing strengthen the validity of our data.
In conclusion, the observation that the distinct methylation profiles
encompassed candidate genes involved in cellular pathways regulating
proliferation and apoptosis in IGHV unmutated and mutated CLL
underlines a critical role for epigenetic changes during leukemogenesis.
Most identified tumor suppressor genes were specifically silenced in
IGHV unmutated CLL, implicating the role of these genes in the
pathogenesis of this subgroup. Specific inhibition of expression of
unmethylated genes involved in facilitating tumorigenesis and reexpres-
sion of methylated candidate tumor suppressor genes within the
poor-prognostic subgroups could represent a possible route for drug
therapy. Hopefully, our results may help to further unravel the pathogen-
esis of CLL and identify possible novel biomarkers and targets for drug
therapy in CLL.
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